Systems to Monitor Testosterone Replacement Therapy (TRT)

Reading Time: 4 minutes [1042 words]

Play

Stop

Systems to Monitor Testosterone Replacement Therapy (TRT)

A grim reality of aging is the decline of our hormones. Beginning at approximately age 30, we begin to lose most hormones at a rate of around 10% per decade, which eventually results in a condition called late-onset hypogonadism (LOH). The drop in testosterone levels (aka “Low-T”) can be particularly debilitating for men. Here are a few of the consequences of testosterone loss:

Chronic fatigue
Loss of strength and muscle mass
Insomnia and an inability to stay asleep
Increased joint aches and pains
Depression
Mental fog and an impaired memory
Dried, wrinkled skin
Erectile dysfunction
Loss of libido
Lower urinary tract issues
And more. All of these symptoms result in a reduced, depleted quality of life (QoL).

Testosterone Replacement Therapy to the Rescue

Testosterone Replacement Therapy (TRT) has been proven to ease – and at times reverse – the procession of the destroyers mentioned above of men’s quality of life. This conclusion about TRT’s benefits is based on the anecdotal testimonials of TRT patients and several medical metrics.

However, to date, there has no one absolute, fool-proof tool to access the quality of life for men undergoing testosterone replacement therapy.

A recent study examined the various ways available to quantify TRT’s benefits.

Low-T causes are numerous, but the research broke them down into two main groups: primary hypogonadism caused by testicular failure or acquired or congenital secondary hypogonadism, which traces the origin of these conditions to the hypothalamus or the pituitary gland.

Hypogonadism is a clinical condition. Questionnaires and scoring systems represent the standard tools to measure the effectiveness of testosterone treatment. While these tools have been somewhat effective, researchers have concluded that a more precise, comprehensive tool is needed when men suffer from erectile dysfunction, depression, or chronic pain.

The study reviewed the available tools that monitor QoL in adult men with LOH taking TRT and provided evidence for the effectiveness and limitations of the tools. Here is a look at the various tools:

The Aging Males’ Symptoms (AMS) scale has been used since 1999 and evaluates the symptoms and severity of Low-T and the patient's response to testosterone treatment. The scale consists of 17 questions concerning symptoms and varies from 17 (minimal significance) to 85 (severe symptoms of Low-T). The questions also ask about insomnia, a common occurrence for hypogonadal men. The tool is quite common and tracks the severity of symptoms and complexity of Low-T.
The androgen deficiency in the aging male (ADAM) questionnaire is another questionnaire used to discover Low-T and its symptoms. This approach asks 10 questions concerning libido, fatigue, mood, chronic pain, and daily activities. ADAM is not used as often as AMS.
The Short-form health survey (SF) focuses on the QoL in patients with chronic conditions, social activities, pain, energy, general health, mental health, and emotions. Initially, the short form survey contained 36 questions, but a shorter version has also been used.
The international prostate symptoms score (IPSS) is designed to monitor the effect of TRT on prostate growth. Some increase in prostate size but no urinary difficulties has been reported in some men undergoing TRT. The link between TRT and prostate problems is not definitive since many of the men on TRT are older and suffer from lower urinary tract symptoms (LUTS) more often than younger men. The score is an early-warning system that may occur during TRT and require immediate treatment.
The International Index of Erectile Function (IIEF) evaluates the severity of Erectile Dysfunction (ED) in men taking testosterone therapy. ED is a frequent symptom of Low-T, and this tool is geared toward assessing sexual vitality and mood. The questionnaire is extensive, consisting of 90 questions.
The Derogatis interview for sexual functioning (DISF-SRII), The daily psychosexual questionnaire (PDQ), and The Male Sexual function inventory (BMSFI) are all similar questionnaires that focus on male sexual health.
Mood swings and depression are other hallmarks of Low-T. As mentioned earlier, the Short-form health survey (SF) is a tried-and-true approach to tracking the mental health of TRT patients. The symptom checklist 90 revised (SCL-90-R) consists of 90 questions and emphasizes the psychological health of mentally ill patients or those in traumatic situations. The questionnaire asks questions about anger and guilt and is used to determine psychological issues in men with Klinefelter syndrome.
The Domains of the AMS questionnaire is administered periodically throughout the TRT regimen. The Hamilton depression rating scale (HAM-D) and the Endicott quality of life enjoyment and satisfaction scale (Q-LES-Q) are used at diagnosis, follow-up, and to watch for relapse.

These psychological assessments are crucial for men during testosterone treatment since most men experiencing the acute adverse effects of Low-T are at high risk of depression, regardless of their age or the cause of their loss of testosterone.

The advantage of these questionnaires is that they are affordable, quick, and easy to conduct and may lead to further understanding and research. The downside is that they may be subject to reporting and confirmation bias and are subjective.

Another downside of these assessment tools is that no one tool covers all bases. The AMS scale and the short-form health survey cover most mental health and well-being areas, but they are not as focused on depression as the extent of the HAM-D scale. But the HAM-D scale does not cover the broad range of questions like the AMS and short-form surveys.

Another area of concern is the possible link between prostate cancer and TRT. The connection has been debunked, but it still remains an area of concern. The key is to measure biochemical markers (e.g., hematocrit, serum testosterone, lipid markers, etc.) throughout the ongoing TRT and treat any adverse developments.

To conclude, the researchers acknowledge the limitations of their study. The determination of the scoring systems was discretionary and based on the researcher’s judgment. The study’s goal was to review the use of these surveys and not perform a qualitative, quantitative, or comprehensive analysis.

The takeaway is this: there is no one perfect tool to measure the psychological well-being of men suffering from hypogonadism and undergoing a TRT regimen. Using a combination of these tools is recommended and targets the main complaint.